Acute response in the noninfarcted myocardium predicts long-term major adverse cardiac events after STEMI

<p><strong>Background: </strong>Acute ST-segment elevation myocardial infarction (STEMI) has effects on the&nbsp;myocardium&nbsp;beyond the immediate infarcted territory. However, pathophysiologic changes in the noninfarcted myocardium and their prognostic implications rema...

Full description

Bibliographic Details
Main Authors: Shanmuganathan, M, Masi, A, Burrage, MK, Kotronias, RA, Borlotti, A, Scarsini, R, Banerjee, A, Terentes-Printzios, D, Zhang, Q, Hann, E, Tunnicliffe, E, Lucking, A, Langrish, J, Kharbanda, R, De Maria, GL, Banning, AP, Choudhury, RP, Channon, KM, Piechnik, SK, Ferreira, VM
Format: Journal article
Language:English
Published: Elsevier 2022
Description
Summary:<p><strong>Background: </strong>Acute ST-segment elevation myocardial infarction (STEMI) has effects on the&nbsp;myocardium&nbsp;beyond the immediate infarcted territory. However, pathophysiologic changes in the noninfarcted myocardium and their prognostic implications remain unclear.</p> <p><strong>Objectives: </strong>The purpose of this study was to evaluate the long-term prognostic value of acute changes in both infarcted and noninfarcted myocardium post-STEMI.</p> <p><strong>Methods: </strong>Patients with acute STEMI undergoing&nbsp;primary percutaneous coronary intervention&nbsp;underwent evaluation with blood biomarkers and&nbsp;cardiac magnetic resonance&nbsp;(CMR) at 2&nbsp;days and 6&nbsp;months, with long-term follow-up for&nbsp;major adverse cardiac events&nbsp;(MACE). A comprehensive CMR protocol included cine, T2-weighted, T2&lowast;, T1-mapping, and late&nbsp;gadolinium&nbsp;enhancement (LGE) imaging. Areas without LGE were defined as noninfarcted myocardium. MACE was a composite of cardiac death, sustained&nbsp;ventricular arrhythmia, and new-onset heart failure.</p> <p><strong>Results: </strong>Twenty-two of 219 patients (10%) experienced an MACE at a median of 4 years (IQR: 2.5-6.0 years); 152&nbsp;patients returned for the 6-month visit. High T1 (&gt;1250&nbsp;ms) in the noninfarcted myocardium was associated with lower&nbsp;left ventricular ejection fraction&nbsp;(LVEF) (51% &plusmn; 8% vs 55% &plusmn; 9%;&nbsp;<em>P =</em>&nbsp;0.002) and higher NT-pro-BNP levels (290 pg/L [IQR: 103-523 pg/L] vs 170 pg/L [IQR: 61-312 pg/L];&nbsp;<em>P =</em>&nbsp;0.008) at 6&nbsp;months and a 2.5-fold (IQR: 1.03-6.20) increased risk of MACE (2.53 [IQR: 1.03-6.22]), compared with patients with normal T1 in the noninfarcted myocardium (<em>P =</em>&nbsp;0.042). A lower T1 (&lt;1,300&nbsp;ms) in the infarcted myocardium was associated with increased MACE&nbsp;(3.11 [IQR: 1.19-8.13];&nbsp;<em>P =</em>&nbsp;0.020). Both noninfarct and infarct T1 were independent predictors of MACE (both&nbsp;<em>P =</em>&nbsp;0.001) and significantly improved risk prediction beyond LVEF, infarct size, and microvascular obstruction (C-statistic: 0.67 &plusmn; 0.07 vs 0.76 &plusmn; 0.06, net-reclassification index: 40% [IQR: 12%-64%];&nbsp;<em>P =</em>&nbsp;0.007).</p> <p><strong>Conclusions: </strong>The acute responses post-STEMI in both infarcted and noninfarcted myocardium are independent incremental predictors of long-term MACE. These insights may provide new opportunities for&nbsp;treatment&nbsp;and&nbsp;risk stratification&nbsp;in STEMI.</p>